⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SCNI News
Scinai Immunotherapeutics Ltd. American Depositary Shares
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
prnewswire.com
SCNI
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
prnewswire.com
SCNI
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
prnewswire.com
SCNI
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
prnewswire.com
SCNI
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
prnewswire.com
SCNI
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
prnewswire.com
SCNI
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept
prnewswire.com
SCNI
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform
prnewswire.com
SCNI
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm
prnewswire.com
SCNI
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL
prnewswire.com
SCNI